Tags

Type your tag names separated by a space and hit enter

Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
Am J Kidney Dis. 2008 Sep; 52(3):475-85.AJ

Abstract

BACKGROUND

In patients with primary glomerulonephritis (GN), antiproteinuric response to angiotensin-converting enzyme (ACE) inhibitors plus angiotensin receptor blockers (ARBs) versus either monotherapy is undefined because of the small size of studies and high heterogeneity of response.

STUDY DESIGN

Meta-analysis/metaregression.

SETTING & POPULATION

Randomized clinical trials (RCTs).

SELECTION CRITERIA FOR STUDIES

RCTs published from January 1996 to April 2007. Studies were excluded if information about levels of proteinuria was not available, patients had kidney disease other than primary GN, or if they had end-stage renal disease.

INTERVENTION

ACE inhibitor plus ARB versus monotherapy with 1 of these drug classes.

OUTCOMES

Absolute changes in proteinuria (primary), blood pressure, serum potassium level, and glomerular filtration rate (GFR; secondary).

RESULTS

We found 13 RCTs including 425 patients with primary GN with proteinuria ranging from 0.8 to 7.9 g/d of protein and age from 25 to 60 years. Combination treatment decreased proteinuria by 0.60 g/d (95% confidence interval, 0.40 to 0.80) versus ACE-inhibitor monotherapy and 0.54 g/d (95% confidence interval, 0.30 to 0.78) versus ARB monotherapy. Baseline levels of proteinuria explained most between-study variability of the antiproteinuric response to combination therapy versus monotherapies. Systolic and diastolic blood pressure, GFR, age, and diagnosis of immunoglobulin A nephropathy did not modify antiproteinuric response. ACE-inhibitor plus ARB therapy did not change GFR, whereas it increased serum potassium levels (by 0.10 mEq/L versus ACE-inhibitor and 0.19 mEq/L versus ARB therapy) and decreased blood pressure.

LIMITATIONS

Only published data are included.

CONCLUSIONS

The antiproteinuric response to ACE-inhibitor plus ARB therapy versus either monotherapy is consistently greater and strictly related to baseline proteinuria, associated with only moderate increase in serum potassium levels, and not peculiar to immunoglobulin A nephropathy.

Authors+Show Affiliations

Nephrology Division at Second University of Naples-S.M.d.P. Incurabili Hospital-ASL Na1, Naples, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

18468748

Citation

Catapano, Fausta, et al. "Antiproteinuric Response to Dual Blockade of the Renin-angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression." American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, vol. 52, no. 3, 2008, pp. 475-85.
Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis. 2008;52(3):475-85.
Catapano, F., Chiodini, P., De Nicola, L., Minutolo, R., Zamboli, P., Gallo, C., & Conte, G. (2008). Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, 52(3), 475-85. https://doi.org/10.1053/j.ajkd.2008.03.008
Catapano F, et al. Antiproteinuric Response to Dual Blockade of the Renin-angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression. Am J Kidney Dis. 2008;52(3):475-85. PubMed PMID: 18468748.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. AU - Catapano,Fausta, AU - Chiodini,Paolo, AU - De Nicola,Luca, AU - Minutolo,Roberto, AU - Zamboli,Pasquale, AU - Gallo,Ciro, AU - Conte,Giuseppe, Y1 - 2008/05/12/ PY - 2007/10/31/received PY - 2008/03/03/accepted PY - 2008/5/13/pubmed PY - 2008/9/19/medline PY - 2008/5/13/entrez SP - 475 EP - 85 JF - American journal of kidney diseases : the official journal of the National Kidney Foundation JO - Am J Kidney Dis VL - 52 IS - 3 N2 - BACKGROUND: In patients with primary glomerulonephritis (GN), antiproteinuric response to angiotensin-converting enzyme (ACE) inhibitors plus angiotensin receptor blockers (ARBs) versus either monotherapy is undefined because of the small size of studies and high heterogeneity of response. STUDY DESIGN: Meta-analysis/metaregression. SETTING & POPULATION: Randomized clinical trials (RCTs). SELECTION CRITERIA FOR STUDIES: RCTs published from January 1996 to April 2007. Studies were excluded if information about levels of proteinuria was not available, patients had kidney disease other than primary GN, or if they had end-stage renal disease. INTERVENTION: ACE inhibitor plus ARB versus monotherapy with 1 of these drug classes. OUTCOMES: Absolute changes in proteinuria (primary), blood pressure, serum potassium level, and glomerular filtration rate (GFR; secondary). RESULTS: We found 13 RCTs including 425 patients with primary GN with proteinuria ranging from 0.8 to 7.9 g/d of protein and age from 25 to 60 years. Combination treatment decreased proteinuria by 0.60 g/d (95% confidence interval, 0.40 to 0.80) versus ACE-inhibitor monotherapy and 0.54 g/d (95% confidence interval, 0.30 to 0.78) versus ARB monotherapy. Baseline levels of proteinuria explained most between-study variability of the antiproteinuric response to combination therapy versus monotherapies. Systolic and diastolic blood pressure, GFR, age, and diagnosis of immunoglobulin A nephropathy did not modify antiproteinuric response. ACE-inhibitor plus ARB therapy did not change GFR, whereas it increased serum potassium levels (by 0.10 mEq/L versus ACE-inhibitor and 0.19 mEq/L versus ARB therapy) and decreased blood pressure. LIMITATIONS: Only published data are included. CONCLUSIONS: The antiproteinuric response to ACE-inhibitor plus ARB therapy versus either monotherapy is consistently greater and strictly related to baseline proteinuria, associated with only moderate increase in serum potassium levels, and not peculiar to immunoglobulin A nephropathy. SN - 1523-6838 UR - https://www.unboundmedicine.com/medline/citation/18468748/Antiproteinuric_response_to_dual_blockade_of_the_renin_angiotensin_system_in_primary_glomerulonephritis:_meta_analysis_and_metaregression_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0272-6386(08)00582-9 DB - PRIME DP - Unbound Medicine ER -